22:21 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

Mereo reports Phase II data for COPD candidate acumapimod

Mereo BioPharma Group plc (LSE:MPH) reported top-line data from a Phase II trial in 282 patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) showing that low- and high-dose acumapimod (BCT-197) plus standard of...
19:10 , May 19, 2017 |  BC Week In Review  |  Clinical News

Mereo completes enrollment in Phase II of acumapimod for COPD exacerbations

Mereo BioPharma Group plc (LSE:MPH) completed enrollment of 282 patients in the international Phase II AETHER trial evaluating acumapimod (BCT-197) to treat acute exacerbations of chronic obstructive pulmonary disease (COPD). The company expects top-line data...
07:00 , Aug 3, 2015 |  BioCentury  |  Finance

From Phase4 to Mereo

The leadership team behind Phase4 Ventures is branching out from its traditional venture roots to launch newco Mereo BioPharma Group Ltd., which aims to provide an alternative for pharmas looking to advance mid-stage pipelines in...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Company News

Novartis, Mereo BioPharma deal

Start-up Mereo acquired three Phase II compounds from Novartis in exchange for an undisclosed equity stake. Novartis is eligible for milestone payments and royalties. BPS-804 is a human mAb for the Orphan bone disease...
01:07 , Jul 30, 2015 |  BC Extra  |  Top Story

Mereo raises $119M, acquires three Novartis programs<span class="*Red-type+bold">

Mereo BioPharma Group Ltd. (London, U.K.) debuted on Wednesday with $119 million (L76.7 million) and three clinical-stage programs acquired from Novartis AG (NYSE:NVS; SIX:NOVN). Woodford Investment Management and Invesco Perpetual invested in Mereo; Novartis also...